Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe
NCT06203119 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2024-08-19
Summary
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the clinical predictive value of 68Ga-DOTA-BPP in subjects with triple-negative breast cancer. The visual and semiquantitative methods will be used to assess the PET/CT images
Conditions
Sponsors & Collaborators
-
Peking University Cancer Hospital & Institute
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-10-01
- Primary Completion
- 2024-10-31
- Completion
- 2024-10-31
Countries
- China
Study Locations
More Related Trials
-
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients
NCT01527058 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
NCT05321316 ·Status: RECRUITING ·Phase: NA
-
68Ga-NYM096 PET/CT in Various Kinds of Cancer
NCT07144748 ·Status: RECRUITING ·Phase: NA
-
PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor
NCT05156515 ·Status: UNKNOWN ·Phase: NA
-
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors
NCT06056362 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors
NCT06994078 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
68Ga-NOTA-RM26 PET/CT in Breast Tumor Patients
NCT03347864 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
NCT05637034 ·Status: UNKNOWN ·Phase: NA
-
An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income Countries
NCT02247713 ·Status: UNKNOWN
-
Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
NCT02817945 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Clinical Study of 68Ga-labeled Novel Nectin-4 Bicyclic Peptide PET/CT for Imaging of Solid Tumors With High Nectin-4 Expression
NCT07319130 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
68Ga-ICAM-1pep PET/CT in Cancer Patients
NCT04596670 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
NCT07331532 ·Status: RECRUITING
-
Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients
NCT06956144 ·Status: RECRUITING
-
Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer
NCT05742269 ·Status: TERMINATED
-
PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy
NCT00019565 ·Status: COMPLETED ·Phase: PHASE1
-
Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions
NCT06648317 ·Status: RECRUITING
-
68Ga-FAPI PET/CT in Patients With Various Types of Cancer
NCT04499365 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
68Ga PET/CT Imaging in Breast Cancer Patients
NCT05622227 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer
NCT01190566 ·Status: COMPLETED
-
PET Imaging of 68Ga-Her2-affibody in Tumors with High Her2 Expression
NCT06289517 ·Status: RECRUITING ·Phase: NA
-
Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB
NCT02496013 ·Status: UNKNOWN ·Phase: PHASE1
-
CD70-targeted immunoPET Imaging of Kidney Cancer
NCT06680089 ·Status: RECRUITING ·Phase: PHASE2
-
Comparison Between ER Loss and Triple-Negative Breast Cancer Guided by 18F-FES PET/CT in Metastatic Breast Cancer
NCT07316439 ·Status: ACTIVE_NOT_RECRUITING
-
18F-LN1 PET/CT in Urothelial Carcinomas
NCT06120413 ·Status: RECRUITING